teratogenicity We conditionally recommend continuation of anakinra and rituximab based on limited data Maternal medication use. Supplementary Appendix 7, Tables I (conventional rheumatology medications), J (biologic rheumatology medications), and K (glucocorticoids) ( http://onlin elibr ary.wiley.com/doi/10.1002/art.41191/ abstract http://onlin elibr ary.wiley.com/doi/10.1002/art.41191/ abstract 3 As standard good practice, we suggest discussing medications well before the patient attempts to conceive; we also suggest discussing pregnancy plans prior to initiating treatment with medications that may affect gonadal function, such as CYC. There are no published data regarding specific timing for medication discussion, which will vary according to the individual clinical situation, but in general we suggest adequate time to allow for appropriate medication changes and demonstration of tolerability and disease stability, usually a minimum of several months. MTX, MMF, CYC, and thalidomide